Company facts
Early-stage
- Founded
- 2017
- Employees
- 2
- Headquarters
- United States
About
Our lead candidate is a multifaceted attack antibody for ovarian cancer. Our approach enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.